Hamlet Pharma AB: New patent to treat and prevent gastrointestinal cancer is in order for grant
HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims to the use of HAMLET or HAMLET-like complexes to treat or prevent gastrointestinal cancer.
The patent application is in order for grant and thus fulfills the criteria to be accepted by the EPO examiners.
The patent application, EP13762204.9, includes claims where complexes including HAMLET are used for the treatment of colon cancer.
In addition, the patent includes a claim where the complexes, which include BAMLET, the bovine alpha-lactalbumin complex, is used for prevention in the form of a nutraceutical.
The next step will be to complete the grant process to secure the final patent.
This is an important addition to the Hamlet Pharma patent family and offers a mechanism for diversification of products developed by the company.